Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company with a novel vaccine platform, have signed a commercial license agreement to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV).
3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement with SpyBiotech, a company with a novel vaccine platform to..